Vesilute Research

The indexed research record for Vesilute is almost empty. Vesilute is a vendor trade name for the dipeptide Glu-Asp. A Russian oral capsule is sold under the near-identical name Vesilut, with one e. PubMed returns no records for either spelling. A Europe PMC full-corpus search returns none for Vesilute and one for Vesilut.

What Vesilute is

The product page declares CAS 3918-84-1, the formula C9H14N2O7, a molecular weight of 262.22 g/mol, and the sequence Glu-Asp. Those values resolve cleanly on PubChem to CID 99716, so the declared identity is internally consistent and the CAS is the right one for the alpha-linked dipeptide. A 1983 X-ray crystallography study of two acidic dipeptides reported it as a zwitterion with a trans peptide bond.^[6] That is structural chemistry rather than pharmacology.

The Russian capsule and the Western vial are not established to be the same substance. The capsule declares its active as peptide AKS-M, given as L-aspartic acid and L-glutamic acid, which names two free amino acids rather than a peptide-bonded molecule. Nothing published reconciles the capsule with the synthetic dipeptide, yet indication claims are carried from one to the other.

Several near neighbors are easy to confuse with this molecule. Asp-Glu, CAS 6157-06-8, is the reverse dipeptide with the same formula, and its name differs only in the order of the two residues. Vesugen, also written KED, is the tripeptide Lys-Glu-Asp and has its own separate literature.^[14] Chitomur is a bovine bladder tissue extract rather than a defined peptide. Vendors do not agree on the sequence they are selling. At least one lists a product as "Vesilut (Lys-Glu-Asp)", which is the tripeptide rather than this molecule.

Where the bladder claim comes from

One indexed paper names Vesilut, a 2022 review with molecular docking from Vladimir Khavinson's group.^[1] Its Table 2 lists "Vesilut (ED)" with an ICM docking score of -34.32 and the activity label "Bladder regulator". That is the top row of the table, the best of its 27 docking scores. A docking score is a computed prediction of binding, here to the LAT1 amino acid transporter. Such a score predicts whether a molecule may be carried into a cell, rather than what it does once there. The paper reports no laboratory experiment on this dipeptide.

That activity label carries no citation. Nine other rows of the same 27-row table are also unreferenced, including Kistiget, the only other peptide the table calls a bladder regulator. So both bladder attributions in that table are unsourced labels rather than reported findings.

The same paper also contradicts itself about the docking target. Its text says Table 2 shows docking in the NSP5 active site, while the table is titled as binding to LAT1. NSP5 is the SARS-CoV-2 main protease.

The compound is absent from the program's own summary of itself. Khavinson's 2021 systematic review of peptide regulation of gene expression contains no occurrence of bladder, urinary, or Vesilut in its full text.^[7] Its only "Glu-Asp" string sits inside a reference title for a different, three-residue peptide.

The one indexed study that gave Glu-Asp to animals

A 1999 study compared five dipeptides against their own constituent free amino acids in mice and in vitro.^[2] The five were GluTrp, LysAsp, LysVal, AspGlu, and GluAsp, so both this dipeptide and its reverse were tested. The endpoints were immune response, phagocytosis modulation, and antitoxic protection. The authors reported no difference between the dipeptides and their constituent amino acids on any of the three, with the two lysine-containing dipeptides excepted. That exception does not reach GluAsp.

It is the closest thing on the indexed record to a test of the bioregulator idea, and it did not examine the bladder. An earlier 1998 paper from the same author reported immune stimulation for GluTrp and LysAsp in animal and in vitro work.^[3] GluAsp is not among the active peptides its abstract lists.

The food-science studies on Glu-Asp

Two primary studies of this exact dipeptide come from food research groups with no connection to the bioregulator program and no commercial stake in it. Neither looked for a tissue-regulating effect.

The first is in vitro receptor work from a Korean food research institute.^[4] Glu-Asp was one of five umami soybean peptides that attenuated salicin-induced calcium influx in cells expressing the human bitter receptor hTAS2R16. A tasteless control peptide did not.

The second is solution chemistry from a Danish food chemistry group.^[5] Calcium affinity for Glu-Asp was measured at Ka 22.7 L/mol, against an additive expectation of 21 L/mol. In the same paper Glu-Glu came out well above its additive expectation and Asp-Asp well below it. So the method detects emergent behavior where it exists, and for Glu-Asp it detected none.

Human research and regulatory status

No human study of Vesilute is indexed in PubMed or Europe PMC. A ClinicalTrials.gov search on the trade name returns no studies. An intervention search on glutamyl-aspartic acid returns only records matching unrelated terms, such as gamma-glutamyl transferase liver panels.

No safety record for this dipeptide is indexed either. The indexed literature contains no absorption, distribution, metabolism, excretion, half-life, dose-ranging, or toxicity study of this dipeptide by any route. No stability or degradation study of it is indexed. Free dipeptides are substrates for serum and brush-border peptidases. Nothing published measures how much of this one survives to reach a transporter, in humans, in animals, or in vitro.

Russian-language journals and registries are poorly indexed internationally. Where this article says something does not exist, that describes the searches, indexes, and registries named in this article, rather than everything that could exist.

Two randomized human studies in older adults are sometimes offered as support.^[8][9] Both are Russian-language 2013 papers and both tested Chitomur. Those two human studies reported improvement with Chitomur and no detected adverse effects, and one was placebo-controlled. Neither administered Glu-Asp. Nothing published identifies this dipeptide as the active constituent of Chitomur. Both human studies are single-center, and both appeared in Advances in Gerontology, a journal affiliated with the institute behind the peptide program. Neither abstract states a sample size. No group outside that network has replicated either one.

The compound holds no approval anywhere, and openFDA queries by substance name, active ingredient, and brand name all return no match. The Russian capsule Vesilut is sold by TD Peptid Bio in the style of that country's supplement register rather than as a registered medicine. Being on sale there is not an approval. An FDA substance registry identifier does exist, UNII 38Y324JU2X. A registry identifier is an index entry and confers no regulatory status.

No patent on the program's own published index claims this dipeptide. That index lists patents on the tripeptide Glu-Asp-Gly, and one Eurasian patent, EA 010722, covering an extract-derived bladder substance. That is the Chitomur route rather than the synthetic molecule. A patent is not an approval in any case.

Independence, and figures that have no source

Every published document connecting Glu-Asp to the bladder traces back to one organization. Khavinson directs the institute behind the peptide program, is a named inventor on that program's patents, and the products carry that branding. The single indexed paper naming Vesilut is that group reviewing its own program. Nothing that program reports about this compound has been independently replicated.

Vendor copy circulates precise comparative figures that have no traceable origin. The claims that this compound acts 20 to 30 percent faster than Chitomur, that Chitomur is roughly 33 percent stronger, and that an aftereffect lasts 6 to 12 months, rest on no published source. No study compares the two substances, and none reports an onset or an aftereffect duration for either. One vendor page also cites papers that never mention this compound, including a 2013 clinical review of seven other preparations.^[10] The padding on that page is wholesale. It also cites research on AOD-9604, on CJC-1295 with ipamorelin, and on BPC-157, none of which concerns Glu-Asp or the bladder.

The gamma-linked isomer, CAS 16804-55-0, is the compound most easily mistaken for this one. It shares the formula C9H14N2O7 and differs only in the peptide linkage. Animal studies of it report impaired memory retention in mice.^[11][12] One of those two papers also reports that it inhibits glutamate binding on hippocampal membranes in vitro.^[12] The other isolated it from the plant Datura stramonium.^[11] A 1979 paper isolated it from pig brain, so it occurs in mammals and not only in plants.^[13] It is a chemically distinct compound, and none of that work is evidence about the alpha-linked dipeptide.

Conclusion

Vesilute is a chemically well-characterized small molecule whose indexed biological research record is almost empty. The bladder attribution originates as an unreferenced label in a docking table. The one indexed study that gave the dipeptide to animals found no difference from its constituent amino acids on the three endpoints it measured. Research-grade Vesilute is supplied for laboratory use. Each absence reported above describes the searches, indexes, and registries named in this article. Russian-language journals and registries are poorly indexed internationally.

Frequently Asked Questions

Has Vesilute been tested in humans?

No human study of Vesilute is indexed in PubMed or Europe PMC. The two randomized human studies sometimes offered as support tested Chitomur, a bovine bladder extract, and neither administered Glu-Asp.^[8][9] Russian-language sources are poorly indexed internationally, so this describes the indexed record.

Is Vesilute the same peptide as Vesugen?

No. Vesugen, also written KED, is the tripeptide Lys-Glu-Asp, a larger molecule with its own literature.^[14] At least one vendor lists a product as "Vesilut (Lys-Glu-Asp)", so the sequence on a label does not always match the name.

Does the docking score mean the compound is potent?

No. The -34.32 figure is a computed prediction of binding to the LAT1 transporter, reported in one review.^[1] It is the best of the 27 scores in that table. A docking score predicts that a molecule may be carried into a cell rather than what it does once there. That paper reports no laboratory experiment on this dipeptide. A predicted binding value is not a measurement of activity.

References

1. 1

   Khavinson V, Linkova N, Kozhevnikova E, Dyatlova A, Petukhov M. Transport of Biologically Active Ultrashort Peptides Using POT and LAT Carriers. Int J Mol Sci. 2022 Jul 13. PMID 35887081
2. 2

   Belokrylov GA, Popova OYa, Sorochinskaya EI. Immuno-, phagocytosis-modulating and antitoxic properties of dipeptides are defined by the activity of their constituent amino acids. Int J Immunopharmacol. 1999 Dec;21(12):879-83. PMID 10606007
3. 3

   Belokrylov GA. Immuno-, phagocytosis-modulating, and antitoxic properties of amino acids and peptide preparations. Drug Dev Ind Pharm. 1998 Feb. PMID 15605441
4. 4

   Kim MJ, Son HJ, Kim Y, Misaka T, Rhyu MR. Umami-bitter interactions: the suppression of bitterness by umami peptides via human bitter taste receptor. Biochem Biophys Res Commun. 2015 Jan 9;456(2):586-90. PMID 25490385
5. 5

   Vavrusova M, Skibsted LH. Calcium binding to dipeptides of aspartate and glutamate in comparison with orthophosphoserine. J Agric Food Chem. 2013 Jun 5;61(22):5380-4. PMID 23682986
6. 6

   Eggleston DS, Hodgson DJ. Conformation and structure of acidic dipeptides. Crystal structures of L-alanyl-L-aspartic acid and alpha-L-glutamyl-L-aspartic acid. Int J Pept Protein Res. 1983 Mar;21(3):288-95. PMID 6853030
7. 7

   Khavinson VK, et al. Peptide Regulation of Gene Expression: A Systematic Review. Molecules. 2021 Nov 22. PMID 34834147
8. 8

   Gomberg VG, et al. [Correction of age related bladder function decrease with peptide geroprotector in women]. Adv Gerontol. 2013. Russian. PMID 28976156
9. 9

   Gomberg VG, et al. [Peptide geroprotector application for treatment of elderly and senile patients with prostatic hyperplasia]. Adv Gerontol. 2013. Russian. PMID 24640697
10. 10

    Khavinson VKh, et al. [Peptide bioregulators: the new class of geroprotectors. Message 2. Clinical studies results]. Adv Gerontol. 2013. Russian. PMID 24003726
11. 11

    Schmitz-Bourgeois M, et al. Isolation and structure of a pseudopeptide gamma-L-glutamyl-L-aspartic acid from Datura stramonium that impairs learning retention. Biochimie. 1988 Sep. PMID 3147710
12. 12

    Ungerer A, et al. gamma-L-glutamyl-L-aspartate induces specific deficits in long-term memory and inhibits [3H]glutamate binding on hippocampal membranes. Brain Res. 1988 Apr 19. PMID 2897230
13. 13

    Cheung ST, et al. Isolation of gamma-glutamylaspartic acid and alpha-aspartylalanine from pig brain. Biochim Biophys Acta. 1979 Aug 22. PMID 476146
14. 14

    Khavinson VK, et al. Peptide KED: Molecular-Genetic Aspects of Neurogenesis Regulation in Alzheimer's Disease. Bull Exp Biol Med. 2021 May. PMID 34173097